News | November 20, 2023
AskBio announces first patient randomized in Phase 1 Trial of AB-1005
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
RHTC will address a long-standing healthcare access issue for all the local population
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Subscribe To Our Newsletter & Stay Updated
